Project Grant R35GM165492
Award Date 8/7/26
Completion Date 7/31/31
Dollars Obligated $451K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute of General Medical Sciences awarded $899,250 to The University of Texas MD Anderson Cancer Center on September 15, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) to develop statistical methods that delineate spatial and temporal patterns of cell-cell interactions in spatial transcriptomics data. The project addresses methodological gaps in assessing cell-cell interactions and their heterogeneity across spatial transcriptomics platforms. The...
- The National Cancer Institute awarded $740,346 to The University of Texas MD Anderson Cancer Center on September 9, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393), a Project Grant classified as assistance funding. MD Anderson will develop efficient methods for measuring and characterizing genetic interactions in cancer cells using a CRISPR/Cas12a-based multiplexing system called IN4MER, which quantitates genetic interactions with five-fold fewer reagents than...
- The National Institutes of Health National Human Genome Research Institute awarded The University of Texas MD Anderson Cancer Center $2,759,668 on July 1, 2026, under the Human Genome Research program (CFDA 93.172) to develop statistical methods and computational tools for three-dimensional spatial transcriptomics analysis. The project addresses analytical barriers that currently hinder biological investigations using 3D spatial transcriptomics by developing three complementary research...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $226,884 on December 18, 2025, under the Cancer Research Manpower program (CFDA 93.398) to develop computational methods for reconstructing the evolutionary trajectory of focal amplifications and structural variants in cancer genomes. The project will produce two complementary approaches for evolutionary reconstruction: Amplicon Gain and Velocity Estimation (AGAVE), which will time when and how quickly...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $131,933 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support spatial and functional profiling of tumor evolution trajectories and microenvironment interactions in VHL-driven renal cancers. The project applies spatially resolved transcriptomics, genomic engineering, and multi-omics methodologies to create a comprehensive spatial atlas of treatment-resistant clear cell renal cell...
- The National Cancer Institute awarded MD Anderson Cancer Center a $1.5 million Cooperative Agreement on July 23, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop clinical-grade combinatorial new approach methodologies (NAMs) assays for colorectal cancer treatment decisions. The recipient will validate three core methodologies—in vitro micro-organospheres (MOSs), in silico DL-Reflect, and VirtualCellTherapy—using clinical samples and patient outcomes across...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $688,073 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop computational approaches that reconstruct the evolutionary history of cancer metastases. The project, led by Dr. Peter Van Loo, applies molecular archeology of cancer methods—DNA sequencing-based approaches that infer tumor evolutionary history—to metastatic disease. The work will advance understanding of how...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Institute of General Medical Sciences awarded $420,476 to the University of Texas Health Science Center at Houston on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support structural and mechanistic studies of eukaryotic gene transcription regulation. The recipient will conduct five years of integrated structural and molecular biology research investigating how the human CDK8 kinase module (comprising MED13, MED12, CDK8, and CYCC)...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...